Barostim™

About CVRx

CVRx is a commercial-stage medical device company with a singular focus on neuromodulation for cardiovascular disease. Its core achievement is the FDA approval and commercialization of Barostim™, a novel Baroreflex Activation Therapy (BAT) for patients with heart failure with reduced ejection fraction (HFrEF) who remain symptomatic despite guideline-directed medical therapy. The company's strategy is to establish Barostim as a standard of care in heart failure by demonstrating its clinical and economic value, expanding physician training, and pursuing label expansions into adjacent cardiovascular indications. CVRx represents a unique, physiology-modifying approach in a crowded device landscape dominated by rhythm management and mechanical support.

About CVRx

CVRx is a commercial-stage medical device company with a singular focus on neuromodulation for cardiovascular disease. Its core achievement is the FDA approval and commercialization of Barostim™, a novel Baroreflex Activation Therapy (BAT) for patients with heart failure with reduced ejection fraction (HFrEF) who remain symptomatic despite guideline-directed medical therapy. The company's strategy is to establish Barostim as a standard of care in heart failure by demonstrating its clinical and economic value, expanding physician training, and pursuing label expansions into adjacent cardiovascular indications. CVRx represents a unique, physiology-modifying approach in a crowded device landscape dominated by rhythm management and mechanical support.

About CVRx

CVRx is a commercial-stage medical device company with a singular focus on neuromodulation for cardiovascular disease. Its core achievement is the FDA approval and commercialization of Barostim™, a novel Baroreflex Activation Therapy (BAT) for patients with heart failure with reduced ejection fraction (HFrEF) who remain symptomatic despite guideline-directed medical therapy. The company's strategy is to establish Barostim as a standard of care in heart failure by demonstrating its clinical and economic value, expanding physician training, and pursuing label expansions into adjacent cardiovascular indications. CVRx represents a unique, physiology-modifying approach in a crowded device landscape dominated by rhythm management and mechanical support.

Therapeutic Areas

Other Heart Failure with Reduced Ejection Fraction (HFrEF) Drugs